Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
about
Barriers to a cure for HIV in womenAnimal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Preexposure prophylaxis for HIV prevention: where have we been and where are we going?Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challengesPreventing HIV infection: pre-exposure and postexposure prophylaxisAntiretroviral pharmacology in mucosal tissuesDivergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) studyPre-exposure Prophylaxis for HIV Prevention: Why, What, Who and HowAntiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxisStampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDSPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionMTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartmentsRectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized miceGlobal expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxisDaily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with menDevelopment of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studiesPreexposure prophylaxis for HIV infection among African womenTenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis.Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.Importance of Drug Pharmacokinetics at the Site of ActionMeasuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.Biomedical prevention: state of the science.Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV preventionSex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.Preventing HIV infection in women.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.Immune activation and HIV persistence: implications for curative approaches to HIV infection.Mapping antiretroviral drugs in tissue by IR-MALDESI MSI coupled to the Q Exactive and comparison with LC-MS/MS SRM assay.Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Short communication: cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tractA multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected menSexually transmitted diseases treatment guidelines, 2015.Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studyHIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.
P2860
Q26768632-0F10CD96-7EBC-4C8E-B286-4287CE967075Q26777022-64AB6DE1-0130-454C-BA4D-AA47535442C4Q26825042-2F737BCA-0C6F-4967-9913-7B7C5EBC155EQ26825641-1A525518-1188-44D2-B881-1F99E72E5AAEQ26828445-AE64DA21-B286-423D-A893-908E6A57C756Q27014675-2CC34590-4673-437E-966A-C14F320C56BFQ27300707-31A0BC6C-2EEC-4FA9-86D9-E55A30DAED17Q28080301-B995687D-7E5C-488F-B9F6-FCC0B20A8951Q28085433-99B5383B-BFC8-4E5F-94B1-A218B4C4B6B4Q28260539-8AA16A10-3EAF-4CF3-AD51-0169F3523360Q28481276-6306124E-F7CB-44E8-9A04-45789B967234Q28485356-6FD74480-02D9-4D25-8821-1469B88599B5Q28488527-D1875961-B6D4-4C10-9868-3A18AC3C7738Q28534412-82DC4C2D-8FF7-47A4-B073-90550F45C980Q28540969-319BD349-432C-45D4-B08E-DDDC4B48739DQ28542608-FC62352C-3253-46DC-9333-9244B24A6C71Q29620077-A9F5B4A5-5CED-4DF8-9564-6001FD7ADC78Q30843736-D60B928C-B15E-453D-9383-79CC63652AE7Q30854994-510E2BF8-271E-4108-B77B-783FF68BD59AQ33593633-9D3DAEFC-8C6F-40BA-98F6-C31B0EEE80F2Q33648045-275FFE76-C066-41B7-AA35-9946DAB3012FQ33678844-9038AEAB-D947-47D9-9ABE-226F4ADE3295Q33763000-FBA6CC06-E761-402E-A1CD-CAA73994A335Q33765795-CD7EDE40-708D-4C30-88A0-6F7FAFF7F783Q33769971-B5B5C800-29E2-4F1D-AD2C-AF69B5E8406EQ33825769-2A85ABD3-B1D0-4142-9EDA-1BFBD7640CD0Q33855156-384CB426-A6A0-4412-B9A0-10749D7F0940Q33888718-F3DE9909-B777-4158-A7E2-0C28E702E0E5Q34034418-A60BACD6-8CDF-4751-B512-A11CA9B6D41CQ34057568-9D8DA194-202A-48AE-9241-E8862E6F0987Q34351320-196C1370-BEEF-428A-99C6-8BB44E03EE1AQ34364249-D28D9511-BE04-449C-B823-91CDE268A43CQ34379806-3E8A579C-8E93-45AA-9A19-E524F3D222F9Q34399668-964673F1-FA43-43E4-8F1A-FAC69CFE5695Q34414539-92235544-ACA3-4059-8ED5-3A993141D842Q34436959-D68AE1FB-A98B-4C9B-98A5-3CD87EC61891Q34479272-F1825809-71C0-4B1B-85B7-DFF1361CEEB3Q34506545-C59930D0-D9C1-4042-BEA8-371ECB5E69F5Q34534986-E8C7FA0E-81CC-418D-BD43-09A8BB0B8842Q34673978-1B8E0BFC-ACEF-4FC4-BC7F-5D4F8181A8A8
P2860
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Penetration of tenofovir and e ...... vention of HIV-1 transmission.
@ast
Penetration of tenofovir and e ...... vention of HIV-1 transmission.
@en
type
label
Penetration of tenofovir and e ...... vention of HIV-1 transmission.
@ast
Penetration of tenofovir and e ...... vention of HIV-1 transmission.
@en
prefLabel
Penetration of tenofovir and e ...... vention of HIV-1 transmission.
@ast
Penetration of tenofovir and e ...... vention of HIV-1 transmission.
@en
P2093
P2860
P921
P1476
Penetration of tenofovir and e ...... vention of HIV-1 transmission.
@en
P2093
Amanda J Jenkins
Angela D M Kashuba
Eric Kraft
Heather A Prince
James F Rooney
Kristine B Patterson
P2860
P304
P356
10.1126/SCITRANSLMED.3003174
P407
P577
2011-12-01T00:00:00Z